Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H. Con. Res. 96-- Establishing the budget for the U.S. Government for FY 2015 and setting forth appropriate budgetary levels for FY 2016 through 2024 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Protecting Access to Medicare Act of 2014
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2014 · first_quarter · 1T
Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage, the essential benefit pkg., and other matters.
HR 4302 Protecting Access to Medicare Act of 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Source: Senate LDA
HR 4302 Protecting Access to Medicare Act of 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 --Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the U.S. Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033. H. J. Res. 59 -- Continuing Appropriations Resolutions, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2013 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033 In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033 In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2013 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the U.S. Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033. H. J. Res. 59 -- Continuing Appropriations Resolutions, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters
Safeguarding America's Pharmaceuticals Act of 2013
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
HR 1919 Safeguarding America's Pharmaceutical Act of 2013 and the Senate "track and trace" legislation
Safeguarding America's Pharmaceuticals Act of 2013
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
Safeguarding America's Pharmaceuticals Act of 2013
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
HR 1919 Safeguarding America's Pharmaceutical Act of 2013 and the Senate "track and trace" legislation
Safeguarding America's Pharmaceuticals Act of 2013
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
VALID Compounding Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
VALID Compounding Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
Drug Quality and Security Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
Drug Quality and Security Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
Pharmaceutical Quality, Security, and Accountability Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
Pharmaceutical Quality, Security, and Accountability Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
Proposing an amendment to the Constitution of the United States to protect the rights of crime victims.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the U.S. Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033. H. J. Res. 59 -- Continuing Appropriations Resolutions, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Proposing an amendment to the Constitution of the United States to protect the rights of crime victims.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Proposing an amendment to the Constitution of the United States to protect the rights of crime victims.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the U.S. Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033. H. J. Res. 59 -- Continuing Appropriations Resolutions, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Proposing an amendment to the Constitution of the United States to protect the rights of crime victims.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Food and Drug Administration Reform Act of 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Prescription Drug User Fee reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S.2516, Food and Drug Administration Safety and Innovation Act. S.3187, Food and Drug Administration Safety and Innovation Act. S.2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Food and Drug Administration Reform Act of 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Food and Drug Administration Reform Act of 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H. Con. Res. 112, Establishing the budget for the US Government for FY 2013. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolutions, 2013.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H. Con. Res. 112, Establishing the budget for the US Government for FY 2013. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolution, 2013.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2013 budget resolution. H. Con.Res 112, Establishing the budget for the US Government for FY 2013 H.R. 5973/S.2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
FDA User Fee Corrections Act of 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
FDA User Fee Corrections Act of 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Prescription Drug User Fee reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S.2516, Food and Drug Administration Safety and Innovation Act. S.3187, Food and Drug Administration Safety and Innovation Act. S.2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Spending Reduction Act of 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H. Con. Res 112, Establishing the budget for the US Government for FY 2013. H.R. 6684, Spending Reduction Act of 2012. H.R. 8, American Taxpayer Relief Act of 2012.
American Taxpayer Relief Act of 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H. Con. Res 112, Establishing the budget for the US Government for FY 2013. H.R. 6684, Spending Reduction Act of 2012. H.R. 8, American Taxpayer Relief Act of 2012.
Continuing Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B issues. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365/Pub. L. 112-25, Budget Control Act of 2011. H.R. 2674, 340B Program Improvement Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation. P.L. 111-148 Patient Protection and Affordable Care Act implementation.
Continuing Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Continuing Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Continuing Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2012 Budget resolutions H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365/Pub. L. 112-25, Budget Control Act of 2011.
Continuing Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Continuing Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Continuing Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Continuing Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Continuing Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement Monitor debt ceiling negotiations. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365/Pub.L. 112-25, Budget Control Act of 2011.
340B Program Improvement Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
340B Program Improvement Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B issues. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365/Pub. L. 112-25, Budget Control Act of 2011. H.R. 2674, 340B Program Improvement Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation. P.L. 111-148 Patient Protection and Affordable Care Act implementation.
340B Program Improvement Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Consolidated Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Consolidated Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Consolidated Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Consolidated Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Consolidated Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Consolidated Appropriations Act, 2012
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Temporary Payroll Tax Cut Continuation Act of 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Comparative Effectiveness H.R. 1 american Rocovery and Reinvestment Act of 2009 S. Con. Res. 13 H. Con. Res. 85
Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Comparative Effectiveness H.R. 1 American Recovery and Reinvestment Act of 2009 S. Con. Res. 13 H. Con. Res. 85
Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Comparative Effectiveness H.R. 1 american Rocovery and Reinvestment Act of 2009 S. Con. Res. 13 H. Con. Res. 85
Making further continuing appropriations for fiscal year 2011, and for other purposes.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011 H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
Making further continuing appropriations for fiscal year 2011, and for other purposes.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare Issues P.L. 111-148 Patient Protection and Affordable Care Act implementation P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-31 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290 H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Making further continuing appropriations for fiscal year 2011, and for other purposes.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011 H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
Making further continuing appropriations for fiscal year 2011, and for other purposes.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare Issues P.L. 111-148 Patient Protection and Affordable Care Act implementation P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-31 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290 H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Patent Reform Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. 515 Patent Reform Act of 2009 S. 610 Patent Reform Act of 2009 H.R. 1260 Patent Reform Act of 2009
Promoting Innovation and Access to Life-Saving Medicine Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 1427 Promoting Innovation and Access to LIfe-Saving Medicine H.R. 1548 Pathways for Biosimilars Act S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Promoting Innovation and Access to Life-Saving Medicine Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine H.R. 1548 Pathways for Biosimilars Act s. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Promoting Innovation and Access to Life-Saving Medicine Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine H.R. 1548 Pathways for Biosimilars Act s. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Pathway for Biosimilars Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine H.R. 1548 Pathways for Biosimilars Act s. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Pathway for Biosimilars Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 1427 Promoting Innovation and Access to LIfe-Saving Medicine H.R. 1548 Pathways for Biosimilars Act S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Pathway for Biosimilars Act
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine H.R. 1548 Pathways for Biosimilars Act s. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Medicare and Medicaid Extenders Act of 2010
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare Issues P.L. 111-148 Patient Protection and Affordable Care Act implementation P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-31 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290 H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Medicare and Medicaid Extenders Act of 2010
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Physician Payment and Therapy Relief Act of 2010
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Physician Payment and Therapy Relief Act of 2010
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare Issues P.L. 111-148 Patient Protection and Affordable Care Act implementation P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-31 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290 H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Medicare Home Infusion Therapy Coverage Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009 S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
Medicare Home Infusion Therapy Coverage Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009 S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
Medicare Home Infusion Therapy Coverage Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009 S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
A bill to restore the application of the 340B drug discount program to orphan drugs with respect to children's hospitals.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
A bill to restore the application of the 340B drug discount program to orphan drugs with respect to children's hospitals.
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Medicare Issues P.L. 111-148 Patient Protection and Affordable Care Act implementation P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-31 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290 H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Medicare Home Infusion Therapy Coverage Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009 S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
Medicare Home Infusion Therapy Coverage Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009 S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
Medicare Home Infusion Therapy Coverage Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009 S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
Physician Payments Sunshine Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S.301 Physician Payments Sunshine Act of 2009
Physician Payments Sunshine Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S.301 Physician Payments Sunshine Act of 2009
Physician Payments Sunshine Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S.301 Physician Payments Sunshine Act of 2009
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011 H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
Patent Reform Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. 515 Patent Reform Act of 2009 S. 610 Patent Reform Act of 2009 H.R. 1260 Patent Reform Act of 2009
Patent Reform Act of 2009
Client: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY · Firm: MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
S. 515 Patent Reform Act of 2009 S. 610 Patent Reform Act of 2009 H.R. 1260 Patent Reform Act of 2009
H. Con. Res. 96-- Establishing the budget for the U.S. Government for FY 2015 and setting forth appropriate budgetary levels for FY 2016 through 2024 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2013 · fourth_quarter · 4@
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the U.S. Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033. H. J. Res. 59 -- Continuing Appropriations Resolutions, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage, the essential benefit pkg., and other matters.
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the U.S. Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033. H. J. Res. 59 -- Continuing Appropriations Resolutions, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2013 · fourth_quarter · Q4
Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage, the essential benefit pkg., and other matters.
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.
Pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: HR. 1919 - Safeguarding America's Pharmaceutical Act of 2013, HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2013 · third_quarter · Q3
Implementation of the new health care reform law -- PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage in the essential benefit pkg., and other matters.
S. Con. Res. 8 --Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters.
HR 1919 Safeguarding America's Pharmaceutical Act of 2013 and the Senate "track and trace" legislation
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033 In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2013 · second_quarter · Q2
Implementation of the new health care reform law -- PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage in the essential benefit pkg., and other matters.
HR 1919 Safeguarding America's Pharmaceutical Act of 2013 and the Senate "track and trace" legislation
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033 In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2013 · first_quarter · 1A
S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters
S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2013 · first_quarter · 1A
Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage in the essential benefit package, and other matters.
FDA related matters including issues related to "biosimilar products", prescription drug "track and trace" and orphan drug products
S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2013 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2012 · fourth_quarter · Q4
340B-related issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
H. Con. Res. 112, Establishing the budget for the US Government for FY 2013. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolution, 2013.
Medicare coverage and reimbursement. H. Con. Res 112, Establishing the budget for the US Government for FY 2013. H.R. 6684, Spending Reduction Act of 2012. H.R. 8, American Taxpayer Relief Act of 2012.
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2012 · third_quarter · Q3
Medicare coverage and reimbursement. H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Prescription Drug User Fee reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S.2516, Food and Drug Administration Safety and Innovation Act. S.3187, Food and Drug Administration Safety and Innovation Act. S.2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2012 · second_quarter · Q2
FY 2013 budget resolution. H. Con.Res 112, Establishing the budget for the US Government for FY 2013 H.R. 5973/S.2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
Medicare coverage and reimbursement. H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
340B-related issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2012 (implemention).
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2012 · first_quarter · Q1
340B-related issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
FY 2013 budget resolutions. H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation) Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2011 · fourth_quarter · 4A
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Prescription Drug User Fee Act reauthorization. Product exclusivity issues. S. 365/Pub. L. 112-25, Budget Control Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implemention)
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2011 · fourth_quarter · Q4
Prescription Drug User Fee Act reauthorization. Product exclusivity issues. S. 365/Pub. L. 112-25, Budget Control Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implemention)
Medicare coverage and reimbursement. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68. H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R.2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2011 · third_quarter · Q3
Medicare coverage and reimbursement Monitor debt ceiling negotiations. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365/Pub.L. 112-25, Budget Control Act of 2011.
H.R. 1249/S.23, America Invents Act
Prescription Drug User Fee Act reauthorization. Product exclusivity issues. S. 365/Pub. L. 112-25, Budget Control Act of 2011. H.R. 2112, Agriculture Appropriations. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2011 · second_quarter · Q2
Patient Protection and Affordable Care Act implementation. P.L. 111-148 Patient Protection and Affordable Care Act implementation. P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation. 340B issues.
Medicare Coverage and reimbursement. P.L. 111-148 Patient Protection and Affordable Care Act implementation. PL. 111-152 Health Care and Education Reconciliation Act of 2010 implementation.
H.R. 1249/S.23, America Invents Act.
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2011 · first_quarter · Q1
Prescription Drug User Fee Act reauthorization.
Patient Protection and Affordable Care Act implementation. P.L. 111-148 Patient Protection and Affordable Care Act implementation. P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation. 340B issues.
Medicare Coverage and reimbursement. P.L. 111-148 Patient Protection and Affordable Care Act implementation. PL. 111-152 Health Care and Education Reconciliation Act of 2010 implementation.
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2010 · fourth_quarter · Q4
Drug Safety/Pedigree Bills P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010
Medicare Issues P.L. 111-148 Patient Protection and Affordable Care Act implementation P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-31 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290 H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2010 · third_quarter · 3A
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine H.R. 1548 Pathways for Biosimilars Act s. 726 Promoting Innovation and Access to Life-Saving Medicine Act
S.717, 21st Century Cancer ALERT Act Issues related to Medicare coverage for certain cancer therapies Issues related to Comparative Effectiveness
S.301 Physician Payments Sunshine Act of 2009
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2010 · third_quarter · Q3
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine H.R. 1548 Pathways for Biosimilars Act s. 726 Promoting Innovation and Access to Life-Saving Medicine Act
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009 S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
S.717, 21st Century Cancer ALERT Act Issues related to Medicare coverage for certain cancer therapies Issues related to Comparative Effectiveness
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY via MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
2010 · second_quarter · Q2
Comparative Effectiveness H.R. 1 American Recovery and Reinvestment Act of 2009 S. Con. Res. 13 H. Con. Res. 85
S.301 Physician Payments Sunshine Act of 2009
S.717, 21st Century Cancer ALERT Act Issues related to Medicare coverage for certain cancer therapies Issues related to Comparative Effectiveness
FDA related matters including issues related to "biosimilar products", prescription drug "track and trace" and orphan drug products
Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage in the essential benefit package, and other matters.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2013 HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013In all of the above specific issues included potential Medicare offsets that might be applied to prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H. Con. Res. 112, Establishing the budget for the US Government for FY 2013. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolutions, 2013.
340B-related issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare coverage and reimbursement H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B-related issues. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
FY 2012 budget resolutions. H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74. H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution throuh 12/17/11, Pub. L. 112-67. H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36. H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. . 112-78. H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FY 2012 Budget resolutions H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365/Pub. L. 112-25, Budget Control Act of 2011.
340B issues. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365/Pub. L. 112-25, Budget Control Act of 2011. H.R. 2674, 340B Program Improvement Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation. P.L. 111-148 Patient Protection and Affordable Care Act implementation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
FY 2012 Budget resolutions.
Prescription Drug User Fee Act reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
H.R. 1249/S.23, America Invents Act.
FY 2012 Budget resolutions.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011 H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
S. 515 Patent Reform Act of 2009 S. 610 Patent Reform Act of 2009 H.R. 1260 Patent Reform Act of 2009
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009 S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
Comparative Effectiveness H.R. 1 american Rocovery and Reinvestment Act of 2009 S. Con. Res. 13 H. Con. Res. 85
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comparative Effectiveness H.R. 1 american Rocovery and Reinvestment Act of 2009 S. Con. Res. 13 H. Con. Res. 85
S.301 Physician Payments Sunshine Act of 2009
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009 S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
H.R. 1427 Promoting Innovation and Access to LIfe-Saving Medicine H.R. 1548 Pathways for Biosimilars Act S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE